Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Emicizumab vs Factor VIII Prophylaxis in Hemophilia A
NCT06938659Phase 3Not yet recruiting
- Sponsor
- Dhaka Medical College
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (3 arms), sponsored by Dhaka Medical College. Primary endpoints: Annualized Bleeding Rate at 6 months, Annualized Joint Bleeding Rate at 6 months and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06938659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938659.